

Luzelena Caro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8270798/publications.pdf>

Version: 2024-02-01

13
papers

425
citations

1040056

9
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

716
citing authors

#	ARTICLE	IF	CITATIONS
1	Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide <scp>1B</scp> clinical probe than rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 587-598.	2.4	138
2	The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. <i>Journal of Gastroenterology</i> , 2017, 52, 520-533.	5.1	70
3	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1546-1553.	3.0	43
4	The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 366-376.e6.	1.3	38
5	PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease. <i>Infectious Diseases and Therapy</i> , 2017, 6, 137-148.	4.0	30
6	Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1130-1136.	2.0	29
7	Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	28
8	Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	13
9	Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 382-391.	1.6	12
10	Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 665-675.	1.9	9
11	Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 324-330.	2.5	7
12	Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 710-717.	3.0	5
13	Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. <i>Clinical Drug Investigation</i> , 2021, 41, 133-147.	2.2	3